Professor Michael S. Hofman
Professor Michael S. Hofman
Consultant Physician, Peter MacCallum Cancer Centre & University of Melbourne
Verified email at petermac.org
Title
Cited by
Cited by
Year
Sensitivity, specificity, and predictors of positive 68Ga–prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and …
M Perera, N Papa, D Christidis, D Wetherell, MS Hofman, DG Murphy, ...
European urology 70 (6), 926-937, 2016
7592016
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
MS Hofman, J Violet, RJ Hicks, J Ferdinandus, SP Thang, T Akhurst, ...
The Lancet Oncology 19 (6), 825-833, 2018
4332018
Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer—updated diagnostic utility, sensitivity, specificity, and distribution …
M Perera, N Papa, M Roberts, M Williams, C Udovicich, I Vela, ...
European urology 77 (4), 403-417, 2020
3012020
International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers
A Biggi, A Gallamini, S Chauvie, M Hutchings, L Kostakoglu, M Gregianin, ...
Journal of Nuclear Medicine 54 (5), 683-690, 2013
2762013
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised …
MS Hofman, N Lawrentschuk, RJ Francis, C Tang, I Vela, P Thomas, ...
The Lancet 395 (10231), 1208-1216, 2020
2752020
Somatostatin Receptor Imaging with 68Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation
MS Hofman, WFE Lau, RJ Hicks
Radiographics 35 (2), 500-516, 2015
2712015
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale
A Gallamini, SF Barrington, A Biggi, S Chauvie, L Kostakoglu, ...
Haematologica 99 (6), 1107, 2014
2302014
High management impact of Ga‐68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours
MS Hofman, G Kong, OC Neels, P Eu, E Hong, RJ Hicks
Journal of medical imaging and radiation oncology 56 (1), 40-47, 2012
2062012
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging …
J Calais, F Ceci, M Eiber, TA Hope, MS Hofman, C Rischpler, ...
The Lancet Oncology 20 (9), 1286-1294, 2019
1642019
Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial
S Siva, M Bressel, DG Murphy, M Shaw, S Chander, J Violet, KH Tai, ...
European urology 74 (4), 455-462, 2018
1402018
Prostate-specific membrane antigen ligands for imaging and therapy
M Eiber, WP Fendler, SP Rowe, J Calais, MS Hofman, T Maurer, ...
Journal of Nuclear Medicine 58 (Supplement 2), 67S-76S, 2017
1292017
Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls
MS Hofman, RJ Hicks, T Maurer, M Eiber
Radiographics 38 (1), 200-217, 2018
1272018
Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019
S Gillessen, G Attard, TM Beer, H Beltran, A Bjartell, A Bossi, A Briganti, ...
European urology 77 (4), 508-547, 2020
1242020
Is there still a role for SPECT–CT in oncology in the PET–CT era?
RJ Hicks, MS Hofman
Nature reviews Clinical oncology 9 (12), 712, 2012
1162012
Quantitative 177Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system
JM Beauregard, MS Hofman, JM Pereira, P Eu, RJ Hicks
Cancer Imaging 11 (1), 56, 2011
1122011
68 Ga-DOTATATE and 18 F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity
CA Chang, DA Pattison, RW Tothill, G Kong, TJ Akhurst, RJ Hicks, ...
Cancer Imaging 16 (1), 1-12, 2016
1002016
Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes
J Violet, P Jackson, J Ferdinandus, S Sandhu, T Akhurst, A Iravani, ...
Journal of Nuclear Medicine 60 (4), 517-523, 2019
972019
68Ga PET/CT ventilation–perfusion imaging for pulmonary embolism: a pilot study with comparison to conventional scintigraphy
MS Hofman, JM Beauregard, TW Barber, OC Neels, P Eu, RJ Hicks
Journal of Nuclear Medicine 52 (10), 1513-1519, 2011
892011
Validating and improving CT ventilation imaging by correlating with ventilation 4D‐PET/CT using 68Ga‐labeled nanoparticles
J Kipritidis, S Siva, MS Hofman, J Callahan, RJ Hicks, PJ Keall
Medical physics 41 (1), 011910, 2014
882014
The tumour sink effect on the biodistribution of 68 Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy
JM Beauregard, MS Hofman, G Kong, RJ Hicks
European journal of nuclear medicine and molecular imaging 39 (1), 50-56, 2012
882012
The system can't perform the operation now. Try again later.
Articles 1–20